Printer Friendly

Global Blood Therapeutics announces new employment inducement grants.

Global Blood Therapeutics announced that on September 1, 2019, the compensation committee of GBT's board of directors granted Eric Fink and 8 new employees options to purchase an aggregate of 47,600 shares of the company's common stock with a per share exercise price of $45.98 and restricted stock units for an aggregate of 54,425 shares of the company's common stock. All of the above-described awards were made under the GBT's Amended and Restated 2017 Inducement Equity Plan. Pursuant to the Plan, the exercise price for the 47,600 shares of the Company's common stock was the closing trading price on August 30, 2019, because there was no closing trading price on September 1, 2019.

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Sep 4, 2019
Words:117
Previous Article:Nuance board of directors declares spin-off dividend of Cerence shares.
Next Article:Compass Diversified receives deferred consideration from Manitoba Harvest sale.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |